HEP-DART 2023
Hacienda del mar, Los Cabos, Mexico / 3-7 December 2023
We are pleased to announce Hep DART 2023 will be held at the Hacienda Del Mar from December 3-7, 2023 in Cabo San Lucas, Mexico.
After the conference in 2021 we sent a survey out to the former participants of Hep DART to assess were the delegates would like to hold the conference. We received an overwhelming response to continue to hold the conference in Cabo San Lucas. Cabo is an ideal location to hold a conference in December. The climate is warm with little chance of rain during that time of the year. This allows us to hold many events outdoors and provide ample space for social distancing. Additionally, the Cabo is a centralized location for international delegates while allowing additional visa access.
The DART series is and in-person meeting designed for vibrant scientific presentations and discussion, as well as for new investigators to meet leaders in their field, benefiting from educational feedback on their work.
The aim of HEP DART 2023 is to assemble clinicians, researchers, basic scientists, nurses and physician assistants together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). This CME-accredited workshop will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer.
History of HEP DART: Frontiers in Drug Development for Hepatology
Since its inception in 1995, HEP DART has provided a cutting-edge platform for tackling challenges in drug development for viral hepatitis and chronic liver disease. Hep DART has been held in-person every other year at various locations. HEP DART assembles clinicians, researchers, basic scientists, nurses and physician assistants together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC).
HEP-DART 2023 Organizing Committee
Raymond F. Schinazi
Emory University, United States
Mark Sulkowski
Johns Hopkins University, United States
Manal El-Sayed
Ain Shams University, Egypt
Eugene Schiff
University of Miami, United States
Andrea Cox
Johns Hopkins Medicine United States
Charles Rice- Emeritus
Rockefeller University United States
HEP-DART 2023: local Scientific Committee
Harvey Alter, NIH, USA
Ralf Bartenschlager, University of Heidelberg, Germany
Mithat Bozdayi, Ankara University, Turkey
Carol Brosgart, University of California, San Francisco, USA
Francis Chisari, The Scripps Research Institute, USA
Adrian Di Bisceglie, Saint Louis University, USA
Geoffrey Dusheiko, University College London, UK
Jordan Feld, Toronto General Hospital, Canada
Michael Fried, University of North Carolina, USA
Robert Gish, Robert G. Gish, Hepatitis B Foundation, USA
Jason Grebely, University of New South Wales, Australia
Harry Janssen, Erasmus Medical Center, the Netherlands
Brent Korba, Georgetown University, USA
Shyamasundaran Kottilil, Maryland University, USA
George Lau, Humanity and Health Medical Center, Hong Kong, China
Stanley Lemon, University of North Carolina, at Chapel Hill, USA
Miriam Levy, University of Western Sydney & University of New South Wales, Australia
Michael Manns, Hannover Medical School, Germany
Patrick Marcellin, Hopital Beaujon, France
Veronica Miller, University of California, Berkley
Ulrike Protzer, Technical University of Munich, Germany
Allison Jilbert, University of Adelaide, Australia
